Paragon Advisors LLC Purchases 6,423 Shares of RxSight, Inc. (NASDAQ:RXST)

Paragon Advisors LLC raised its position in shares of RxSight, Inc. (NASDAQ:RXST) by 20.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 37,822 shares of the company’s stock after purchasing an additional 6,423 shares during the quarter. Paragon Advisors LLC’s holdings in RxSight were worth $1,300,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of RXST. Amalgamated Bank grew its holdings in shares of RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after buying an additional 207 shares during the last quarter. Principal Financial Group Inc. boosted its stake in RxSight by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 36,046 shares of the company’s stock valued at $1,782,000 after purchasing an additional 240 shares during the last quarter. Quarry LP boosted its stake in RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of RxSight by 5.0% in the 2nd quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock worth $467,000 after purchasing an additional 373 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of RxSight by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,911 shares of the company’s stock worth $1,034,000 after purchasing an additional 399 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors.

Insider Transactions at RxSight

In other news, Director Jesse Anderson Corley bought 11,111 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were bought at an average price of $45.37 per share, for a total transaction of $504,106.07. Following the purchase, the director now owns 468,571 shares in the company, valued at approximately $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at approximately $2,103,005.88. The trade was a 6.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,002 shares of company stock worth $1,959,796 in the last three months. Corporate insiders own 9.36% of the company’s stock.

RxSight Trading Down 3.1 %

RXST opened at $33.43 on Monday. The firm’s 50 day simple moving average is $41.02 and its two-hundred day simple moving average is $47.58. The company has a market capitalization of $1.35 billion, a PE ratio of -40.28 and a beta of 1.20. RxSight, Inc. has a 1-year low of $32.85 and a 1-year high of $66.54.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on RXST shares. Stifel Nicolaus downgraded RxSight from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $65.00 to $40.00 in a report on Friday, December 20th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $42.00 price target (down from $56.00) on shares of RxSight in a research note on Wednesday, December 11th. Jefferies Financial Group assumed coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective on the stock. Finally, UBS Group started coverage on shares of RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 target price for the company. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $59.00.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.